Susceptibility testing, empowered

Welcome to susceptibility testing, empowered

Your newsletter is dedicated to exploring topics relating to antimicrobial susceptibility testing (AST), brought to you by our in-house experts. We look at everything from topics in the news, to emerging technology, pushing AST stewardship to the next level.

Have you signed up to our newsletter?

Sign up now

 

susceptibility testing, empowered: Issue 3

Read articles from the latest issue below


Accurate antimicrobial resistance surveillance testing supporting One Health Initiatives

Accurate antimicrobial resistance surveillance testing supporting One Health Initiatives

Infections originating from foodborne bacteria are becoming more challenging to treat due to increasing levels of antimicrobial resistance. The global One Health initiative in combatting AMR has resulted in various surveillance programs, including that set by European Commission and European Food Safety Authority.

Read more


Verification of new AST testing systems

Verification of new AST testing systems

Ready to implement a new antimicrobial susceptibility testing system into your laboratory? Even with a readymade solution, laboratories are often required to verify the performance of a new method in their own laboratory environment. Learn more about verification recommendations.

Read more

Innovation in antimicrobial development

Innovation in antimicrobial development

We all understand the importance of AST and MIC surveillance in the global AMR stewardship effort. We are well versed in this arena, but with new antibiotic cefiderocol’s unique mode of action, we require a unique method of MIC – one that involves different testing conditions to those used for existing treatment options.

Read more

A Renaissance in Phage Therapy?

A Renaissance in Phage Therapy?

Hear from our first guest editor, Professor Martha Clokie, as we explore the novel potential treasure trove of bacteriophages, taking a look back at past uses as well as looking forward to alternative therapies of the future.

Read more

Discordant antibiotic use can be common, and deadly

Discordant Antibiotic Use Can be Common, and Deadly

Empiric antibiotic therapy in suspected bloodstream infections is vital.  Unfortunately, a new study shows that discordant use is both fairly common, and potentially lethal. Knowing what data from the microbiology laboratory can help optimize the use of empiric therapy is essential to potentially saving lives.

Read more


Previous issues of susceptibility testing, empowered:

Looking into the future of AST

Looking into the future of Antimicrobial Susceptibility Testing (AST)

View our webinar with renowned expert Dr. Rafael Canton, as he explores why rapid antimicrobial susceptibility testing is so important at a time when antibiotic resistance is growing into one of the biggest challenges the world faces today.

Watch webinar

Sepsis Awareness Month

Explore the relationship between coronavirus, sepsis and the rise in antimicrobial resistance

As we continue to adapt and respond to coronavirus, we’re also mindful of its potential connection to other life-threatening conditions, such as sepsis and the impact on antimicrobial resistance. Since the World Health Organization declared coronavirus a global health emergency, there is now more scientific data available to link coronavirus to sepsis.

Read more

World Quality Day

World Quality Day is coming. But what does it mean to AST?

It's World Quality Day, on November 12th, 2020. In order to celebrate a globally established event we’ve explored the connection between quality and antimicrobial susceptibility testing from the perspective of our business, as a manufacturer, and the products you use as a healthcare provider.

Read more

Support your immunocompromised patients

Support your immunocompromised patients

Three new Research Use Only (RUO) Thermo Scientific™ Sensititre™ plates for Nontuberculous Mycobacteria (NTM), provide the most up-to-date recognized drugs available to treat clinically significant NTMs1. In particular, the introduction of a new Nocardia format supports adoption of the latest CLSI guidelines for management of the immunocompromised patient groups most affected by infections related to this organism. The addition of the antibiotic Clofazimine, also provides additional guidance and treatment options in multi-drug resistant isolates. Find out more about these products and The World Health Organizations’ focus to end the TB epidemic by 2030.

Read More

Increases in Ventilator Associated Pneumonuas (VAP) due to coronavirus

Increases in Ventilator Associated Pneumonias (VAP) due to coronavirus

The clinical microbiology team here at Thermo Fisher Scientific™ are in constant contact with healthcare workers dealing with coronavirus globally. Recently we received some important feedback which resulted in us supporting our customers implementing new testing workflows for coronavirus including adding Thermo Scientific™ Sensititre™ System testing options to support their laboratories increased demands for Candida albicans associated Ventilator Assisted Pneumonia (VAP). Visit the microbiology coronavirus support page.

Visit our support page

Anaerobe testing

Anaerobe testing

Antibiotic resistance in anaerobes has been increasing for decades**, with recent focus on Moxifloxacin and most recently Carbapenems. EUCAST states that “Disk diffusion criteria for antimicrobial susceptibility testing of anaerobes have not yet been defined and an MIC method should be used"***. However, running individual MIC tests can be costly, slow and may end up reducing the number of therapeutic options available to patients suffering from intra-abdominal, genital tract, surgical site, brain abscesses and skin and soft tissue infections. A growing number of European hospitals are now testing 13 antibiotics in a single semi-automated test with full traceability.

Find out more

Ceftolozane/tazobactam disc diffusion now available from Thermo Scientific™ Oxoid™

Ceftolozane/tazobactam disc diffusion now available from Thermo Scientific™ Oxoid™

Thermo Scientific™ Oxoid™ Ceftolozane/tazobactam C/T40 (product code CT1970B) discs are now available, and meet both the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) standards. Ceftolozane/tazobactam (ZERBAXA) is approved by the FDA in the United States and is indicated in adult patients for the treatment of complicated urinary tract infections (cUTI), and is also indicated for use in adult patients for the treatment of complicated intra-abdominal infections (cIAI). Both indications have been approved by the European Medicines Agency (EMA). ZERBAXA's latest label approval by the FDA includes hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), with EMA also reviewing this indication.

Get information

* CLSI. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. 3rd ed. CLSI standard M24. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

** Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015;31:4–10.

*** https://www.eucast.org/clinical_breakpoints/